Nuvo Pharmaceuticals (OTCMKTS:NRIFF) Issues Quarterly Earnings Results

Nuvo Pharmaceuticals (OTCMKTS:NRIFF) posted its quarterly earnings results on Wednesday. The company reported ($0.54) earnings per share (EPS) for the quarter, Morningstar.com reports. The firm had revenue of $12.40 million during the quarter. Nuvo Pharmaceuticals had a negative net margin of 44.15% and a negative return on equity of 21.93%.

Nuvo Pharmaceuticals stock opened at $0.51 on Friday. The business’s 50-day simple moving average is $0.54 and its 200 day simple moving average is $1.21. Nuvo Pharmaceuticals has a 12-month low of $0.45 and a 12-month high of $2.48. The company has a current ratio of 2.60, a quick ratio of 1.91 and a debt-to-equity ratio of 9.22.

About Nuvo Pharmaceuticals

Nuvo Pharmaceuticals Inc, a commercial healthcare company, produces and sells pharmaceutical products in the United States, Canada, and Europe. It offers Pennsaid, a topical pain product that is used to treat the signs and symptoms of osteoarthritis of the knee; Pennsaid 2%, a follow-on product to Pennsaid for the treatment of the pain of osteoarthritis of the knee; Heated Lidocaine/Tetracaine (HLT) Patch, a topical patch that provides local analgesia prior to painful needle procedures, such as dialysis, blood draws, and pediatric needles; and Resultz, an over-the-counter product intended to kill head lice and remove their eggs from hair.

Read More: What moving averages are used to define a golden cross?

Earnings History for Nuvo Pharmaceuticals (OTCMKTS:NRIFF)

Receive News & Ratings for Nuvo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.